Shares of Gilead Sciences, Inc. (NASDAQ:GILD) have been assigned a consensus rating of “Buy” from the thirty-three research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, fourteen have assigned a hold recommendation, sixteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $84.23.

A number of equities research analysts have recently commented on GILD shares. Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price target for the company in a report on Friday, October 13th. Berenberg Bank set a $96.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Thursday, October 19th. BMO Capital Markets lowered their price target on shares of Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a report on Friday, October 27th. Credit Suisse Group reiterated a “buy” rating and set a $82.00 price target on shares of Gilead Sciences in a report on Thursday, December 7th. Finally, Mizuho lifted their price target on shares of Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, November 8th.

In other Gilead Sciences news, insider John C. Martin sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $73.62, for a total transaction of $3,681,000.00. Following the completion of the sale, the insider now directly owns 3,046,766 shares in the company, valued at $224,302,912.92. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $73.87, for a total transaction of $1,108,050.00. Following the sale, the executive vice president now owns 64,613 shares of the company’s stock, valued at $4,772,962.31. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 461,666 shares of company stock valued at $34,072,567. 1.30% of the stock is owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its position in shares of Gilead Sciences by 1.9% during the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after purchasing an additional 1,937,031 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Gilead Sciences by 2.4% during the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after purchasing an additional 2,148,697 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Gilead Sciences by 1.0% during the second quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock worth $2,185,784,000 after purchasing an additional 310,607 shares in the last quarter. FMR LLC lifted its position in shares of Gilead Sciences by 1.1% during the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after purchasing an additional 258,005 shares in the last quarter. Finally, Northern Trust Corp lifted its position in shares of Gilead Sciences by 0.7% during the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after purchasing an additional 116,780 shares in the last quarter. Institutional investors own 75.94% of the company’s stock.

Shares of Gilead Sciences (GILD) traded up $0.62 during midday trading on Monday, hitting $74.52. 7,897,600 shares of the stock were exchanged, compared to its average volume of 7,400,000. The stock has a market capitalization of $98,130.00, a P/E ratio of 8.48, a PEG ratio of -1.57 and a beta of 1.13. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $86.27. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. The business had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company’s quarterly revenue was down 13.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.75 earnings per share. analysts expect that Gilead Sciences will post 8.53 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Thursday, December 28th. Investors of record on Friday, December 15th were issued a $0.52 dividend. The ex-dividend date was Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.79%. Gilead Sciences’s payout ratio is 23.66%.

WARNING: “Gilead Sciences, Inc. (GILD) Receives $84.17 Average Price Target from Analysts” was originally posted by Marea Informative and is owned by of Marea Informative. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at https://www.mareainformativa.com/2018/01/29/gilead-sciences-inc-gild-receives-84-17-average-price-target-from-analysts-updated-updated-updated.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.